Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $2.3 million.

  • Gyre Therapeutics' Capital Expenditures fell 3.61% to $668,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $981,000, marking a year-over-year decrease of 79.15%. This contributed to the annual value of $2.3 million for FY2024, which is 72.82% down from last year.
  • Per Gyre Therapeutics' latest filing, its Capital Expenditures stood at $2.3 million for FY2024, which was down 72.82% from $8.5 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Capital Expenditures ranged from a high of $8.5 million in FY2023 and a low of $839,000 during FY2021.
  • Over the past 3 years, Gyre Therapeutics' median Capital Expenditures value was $5.0 million (recorded in 2022), while the average stood at $5.3 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 494.16% in 2022, then slumped by 72.82% in 2024.
  • Yearly analysis of 4 years shows Gyre Therapeutics' Capital Expenditures stood at $839,000 in 2021, then spiked by 494.16% to $5.0 million in 2022, then spiked by 70.85% to $8.5 million in 2023, then tumbled by 72.82% to $2.3 million in 2024.